![]() ![]() ![]() Pfizer markets its oral COVID-19 treatment under the name PAXLOVID™, which is authorized by U.S. ![]() ![]() TPL will launch the product after obtaining necessary approval from Regulatory Agencies. The oral COVID-19 treatment comprises of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating and ritonavir, which slows down nirmatrelvir's breakdown to help it remain in the body for a longer period at higher concentrations. (Pfizer) granting MPP with the rights to sub-license manufacture and commercialisation rights to sub-licensees. Torrent Pharmaceuticals Limited (herein after referred to as "TPL") has announced that it has signed a non-exclusive, non-transferable, non-sub licensable, license agreement to use the patents and know-how in relation to the compound nirmatrelvir with Medicine Patent Pool (herein after referred to as "MPP") for manufacture and commercialisation of the generic version of PAXLOVID™ in 95 low and middle income countries including India for treatment and/or prevention of COVID-19 caused by SARSCoV-2.Įarlier, MPP had entered into license agreement with PF Prism Holdings B.V. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |